Benign prostatic hyperplasia (BPH) remains a hot topic in urological research—more than 800 manuscripts were published on this subject in 2014. The most important advances included improvements in the understanding of the pathophysiology of lower urinary tract symptoms (LUTS) and the medical and surgical management of BPH and LUTS, with a particular focus on new combination strategies and advances in surgical technologies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garraway, W. M., Collins, G. N. & Lee, R. J. High prevalence of benign prostatic hypertrophy in the community. Lancet 338, 469–471 (1991).
Gravas, S. et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology [online], (2014).
McVary, K. T. et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 185, 1793–1803 (2011).
Silva, J., Silva, C. M. & Cruz, F. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr. Opin. Urol. 24, 21–28 (2014).
Drake, M. J. et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.07.013.
Tubaro, A., De Nunzio, C., Puccini, F. & Presicce, F. The evolving picture of lower urinary tract symptom management. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.10.016.
Oelke, M., Giuliano, F., Baygani, S. K., Melby, T. & Sontag, A. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised placebo-controlled study. BJU Int. 114, 568–575 (2014).
Cindolo, L. et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.11.006.
Bachmann, A. et al. A European multicenter randomized noninferiority trial comparing 180 W GreenLight-XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. J. Urol. http://dx.doi.org/10.1016/j.juro.2014.09.001.
Cantwell, A. L. et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 113, 615–622 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Nunzio, C., Tubaro, A. Innovations in medical and surgical treatment. Nat Rev Urol 12, 76–78 (2015). https://doi.org/10.1038/nrurol.2014.360
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.360
